SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

July 06, 2011 06:00 ET

Radient Pharmaceuticals Appoints Dilek Mir as Director of Business Development and Investor Relations

TUSTIN, CA--(Marketwire - Jul 6, 2011) - Radient Pharmaceuticals Corporation "the Company" or "RPC" (OTCQX: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has appointed Dilek Mir as Director of Business Development and Investor Relations. Ms. Mir brings to RPC extensive industry knowledge in both investor relations and medical diagnostics. In this position Ms. Mir will oversee investor relations, new business development, reimbursement strategy, and intellectual property strategy.

Ms. Mir has been an investor relations professional for 13 years. As an executive at Los Angeles and New York based investor relations agencies, she has advised and represented dozens of publicly traded technology and healthcare companies. Healthcare clients have included leaders in their product categories, as well as emerging companies subsequently sold to global healthcare giants.

She has been engaged in technology transfer in both the healthcare and high-tech fields. As an entrepreneur she is founder of ProteaSure, developer of a proteomic in-vitro diagnostic for endometrial cancer. Prior, she had founded, built and sold Polyglot International, the first privately owned language training firm in Moscow, which served over a dozen Fortune 500 clients. Ms. Mir sold Polyglot to Nord Anglia PLC, a global leader in private education.

She serves as Managing Director at Corporate Profile, a boutique New York based investor relations firm. Ms. Mir received her Bachelor of Science in Finance and Political Science from the University of Massachusetts and her M.B.A. from Babson College in Wellesley, Massachusetts.

"Dilek's blend of expertise in both investor relations and medical diagnostics will support our efforts for highly transparent and effective communications while we also putting greater resources into new business development," stated Radient Pharmaceuticals Chairman and CEO Douglas MacLellan. "We are grateful to Kristine Szarkowitz, our former investor relations director, for her great work and professionalism."

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.

The following table is intended to provide the latest information on RPC's business metrics.

RPC's Business Metrics
Cash on hand: $1.4 million*

*Approximate amount as of July 5, 2011
Shares Outstanding: 174 million*

*Approximate number as of July 5, 2011 and there are 200 million shares fully authorized.
Outstanding Warrants & Options: 138.7 million*

*Approximate number as of July 5, 2011

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.